INCYTE CORP — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Incyte completed acquisition of Vega Therapeutics (owned by Star Therapeutics) for $1.25 billion upfront, with up to $750 million in sales milestone payments, adding latarcibart (a Phase 3 monoclonal antibody for von Willebrand disease) to its pipeline. The company raised 2026 total net sales guidance to $5,130–$5,260M (prior: $4,770–$4,940M) and Opzelura guidance to $1,050–$1,100M (prior: $750–$790M), reflecting a $246M one-time CMS settlement benefit and improved gross-to-net profile. Q2 2026 net sales grew 40% YoY to $1.49B; Opzelura surged 173% to $450M, Hematology/Oncology rose 69% to $222M.
Why this rating
Vega acquisition ($1.25B upfront = 11% of market cap) is material but mid-stage asset; CMS settlement is one-time benefit. Strong Q2 growth and raised guidance offset by elevated R&D spending ($1.27B IPR&D charge Q3 2026). Moderate trajectory impact.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.